Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1/P...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2019-10-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/28/153/190058.full |